EV-103 Study by Dr. Jonathan Rosenberg led to the FDA Approval of Enfortumab + Pembrolizumab

Discussing the EV-103 Cohort K study, which resulted in the FDA approval of Enfortumab Vedotin + Pembrolizumab FDA Approval in the Cisplatin ineligible advanced urothelial carcinoma patients. In discussion with the lead author, Dr. Jonathan Rosenberg – Chief of Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center.